Ovarian function suppression

DRUG2 trials

Sponsors

First Affiliated Hospital, Sun Yat-Sen University, Hebei Medical University Fourth Hospital

Conditions

Breast Cancer

Phase 2

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

CompletedNCT04465097

First Affiliated Hospital, Sun Yat-Sen UniversityBreast Cancer

Start: 2020-07-08End: 2023-10-01Updated: 2023-10-17

QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

Not yet recruitingNCT07782840

Hebei Medical University Fourth HospitalBreast Cancer

Start: 2026-10-01End: 2028-12-01Target: 40Updated: 2026-08-26

Related Papers

Abstract P5-09-05: A phase II, single-arm study of histone deacetylases inhibitor Tucidinostat and Exemestane as neoadjuvant therapy in patients with hormone receptor positive HER2 negative breast cancer (NeoTEE trial)

Cancer Research2023-03-012 citations